[HTML][HTML] Alzheimer disease therapy: can the amyloid cascade be halted?
TE Golde - The Journal of clinical investigation, 2003 - Am Soc Clin Investig
The Journal of clinical investigation, 2003•Am Soc Clin Investig
Nonstandard abbreviations used: Alzheimer disease (AD); amyloid β peptide (Aβ); late-
onset AD (LOAD); amyloid β protein precursor (APP); secreted derivative of amyloid β
protein precursor (sAPP); carboxy-terminal fragment (CTF); presenilin (PS); British familial
dementia (BFD); familial Danish dementia (FDD); neurofibrillary tangle (NFT); frontotemporal
dementia with parkinsonism (FTDP); β-secretase (BACE1, for β-site APP-cleaving enzyme);
Food and Drug Administration (FDA); cerebrospinal fluid (CSF).
onset AD (LOAD); amyloid β protein precursor (APP); secreted derivative of amyloid β
protein precursor (sAPP); carboxy-terminal fragment (CTF); presenilin (PS); British familial
dementia (BFD); familial Danish dementia (FDD); neurofibrillary tangle (NFT); frontotemporal
dementia with parkinsonism (FTDP); β-secretase (BACE1, for β-site APP-cleaving enzyme);
Food and Drug Administration (FDA); cerebrospinal fluid (CSF).
Nonstandard abbreviations used: Alzheimer disease (AD); amyloid β peptide (Aβ); late-onset AD (LOAD); amyloid β protein precursor (APP); secreted derivative of amyloid β protein precursor (sAPP); carboxy-terminal fragment (CTF); presenilin (PS); British familial dementia (BFD); familial Danish dementia (FDD); neurofibrillary tangle (NFT); frontotemporal dementia with parkinsonism (FTDP); β-secretase (BACE1, for β-site APP-cleaving enzyme); Food and Drug Administration (FDA); cerebrospinal fluid (CSF).
The Journal of Clinical Investigation